south african health products regulatory authority

South African health regulators—the South African Health Products Regulatory Authority (SAHPRA), the South African Pharmacy Council (SAPC), and the Health Professions Council of South Africa (HPCSA)—have issued a stern warning to medical professionals: continuing to prescribe, dispense, or stock recalled iDEXIS weight-loss injections will result in formal disciplinary action. The products, which include various formulations of semaglutide and tirzepatide, were classified as a Class I, Type A recall in June due to critical safety concerns and regulatory breaches.

Regulatory Enforcement and Professional Consequences

Regulators are moving beyond simple warnings, signaling that they intend to hold individual practitioners accountable. According to the joint statement released by the three bodies, any healthcare professional found to be in possession of, or actively prescribing, the recalled iDEXIS products risks formal disciplinary proceedings under the Medicines and Related Substances Act, 101 of 1965.

SAPC Registrar and CEO Vincent Tlala emphasized the severity of these sanctions, noting that pharmacists and pharmacy support personnel could face the removal of their names from the professional register. The regulators argue that because the products were recalled due to significant safety risks, any practitioner continuing to supply them is “knowingly” endangering public health.

Did you know?

A Class I, Type A recall is the most serious category of medicine recall issued by SAHPRA.

Findings from the iDEXIS Inspection

The regulatory crackdown follows a joint inspection conducted in May at the premises of iDEXIS (Pty) Ltd, which trades as Sentra Pharmacy in Silverton, Pretoria. SAHPRA and the SAPC uncovered several “critical regulatory breaches” during the site visit.

Key findings reported by the regulators include:

Illegal Sourcing: The unauthorized importation of active pharmaceutical ingredients (APIs).
Lack of Quality Control: An absence of testing to verify the potency, purity, and identity of the finished products.
Manufacturing Risks: Inadequate sterile conditions, which regulators warned created an elevated risk of contamination.
Pharmacovigilance Failures: The company lacked a system to monitor and report adverse drug reactions, despite reports of patients being hospitalized after using the products.

The Legal Dispute Over Compounded Medicines

While regulators maintain that the products pose a direct threat to public safety, iDEXIS has contested the findings. The company asserts that its compounding processes are fully compliant with the Medicines and Related Substances Act and the relevant Good Pharmacy Practice Guidelines.

iDEXIS maintains that its APIs are sourced from internationally approved manufacturers and have been independently tested. The company claims that over 200,000 patients have utilized its compounded medicines without reported adverse reactions. However, the Gauteng High Court in Pretoria ruled in June that iDEXIS had been manufacturing large quantities of injections using an unregistered form of semaglutide. The court clarified that only registered APIs may be used when compounding medicine for specific patients on an individual prescription basis.

Future Trends in GLP-1 Regulation

The global surge in demand for drugs like Ozempic, Wegovy, and Mounjaro has outstripped supply, creating a vacuum often filled by compounded alternatives.

Pro Tip: Patients currently using weight-loss injections should verify the registration status of their medication via the official SAHPRA website to ensure their batch is not part of an active recall.

Frequently Asked Questions

Why were the iDEXIS products recalled?

SAHPRA issued a Class I, Type A recall due to critical regulatory breaches, including illegal importation of ingredients, lack of product testing, and inadequate sterile manufacturing conditions.

Can a pharmacist still dispense these products?

No. The SAPC and SAHPRA have explicitly warned that any pharmacist or medical practitioner found dispensing or stocking these recalled products will face formal disciplinary action and potential removal from the professional register.

How can I check if my medication is safe?

Patients are directed to consult the official SAHPRA recall notice, which provides a comprehensive list of all affected batches. If you have concerns, contact your prescribing doctor immediately.

Have you been affected by medication recalls? Share your thoughts or questions in the comments below, and subscribe to our newsletter for the latest updates on health policy and regulatory changes.

Why is Ashwagandha Use Surging in South Africa?

The rapid adoption of ashwagandha is tied to a widespread increase in mental health struggles following the COVID-19 pandemic. According to Bonga Chiliza, head of the department of psychiatry at the University of KwaZulu-Natal (UKZN), the herb’s popularity reflects a public desperate for accessible tools to manage anxiety and depression. Data from Grand View Research identifies South Africa as the leading consumer of the herb within the Middle East and Africa region, with projections suggesting the market could reach USD 15.7 million by 2033.

Did you know?
Research led by Wits University indicates that over 25% of South Africans exhibit clinical symptoms of moderate to severe depression, a trend exacerbated by the economic and social disruptions of the pandemic.

What Are the Risks of Unregulated Supplementation?

Because ashwagandha is sold as a complementary medicine, it lacks the strict prescription controls of conventional pharmaceuticals. Dr. Ashleigh Craig, a researcher involved in Wits University mental health studies, noted that the pandemic severely limited access to formal psychiatric care, leaving many to turn to over-the-counter alternatives. Professor Chiliza warns that this creates a “dosing” vacuum where consumers rely on social media advice rather than medical supervision. He emphasizes that the herb, while plant-based, is processed by the liver and can interact negatively with other medications.

How Do Users Experience Side Effects?

The intensity of the herb’s effects can vary significantly by individual. One anonymous user in his late 20s reported experiencing severe dizziness and a sense of detachment after taking two capsules. “My mind was no longer there,” he said, describing a physical sensation so strong he feared he might collapse while commuting. While he noted that the symptoms subsided as he continued usage, these accounts highlight the potential for adverse reactions when consumers experiment with dosages without medical oversight.

Pro Tip:
Always consult with your prescribing physician before adding supplements to your routine, especially if you are currently taking antidepressants or other mood-regulating medications.

Frequently Asked Questions

Is ashwagandha safe to take with antidepressants?

Professor Bonga Chiliza cautions against stopping prescribed antidepressants to switch to ashwagandha. Always consult your doctor, as herbal supplements can cause dangerous drug-drug interactions.

Prof Bonga Chiliza | Covid 19 And Mental Health_Medtalks ZA

What does the law say about ashwagandha in South Africa?

SAHPRA classifies it as a Category D medicine. It is intended for the relief of mild sleeplessness and fatigue but is contraindicated for individuals with thyroid or autoimmune conditions.

Why is the market for this herb growing so quickly?

Analysts at Grand View Research attribute the growth to evolving wellness trends and a rising demand for over-the-counter mental health support in the wake of the COVID-19 pandemic.

Have you tried herbal supplements for stress management, or do you prefer traditional psychiatric care? Share your experiences in the comments below or subscribe to our health newsletter for the latest updates on wellness regulation in South Africa.